Differences in blood microRNA and circulating tumor cells during immunotherapy
Official title: The Difference of microRNA Signature(S) and Circulating Tumor Cells in Blood Among Cancer Patients Before and Afte Immunotherapy
Run by Chang Gung Memorial Hospital · NCT07260370 · Data updated 2026-11-12
This project will test whether levels of microRNA and circulating tumor cells in the blood change before and after immunotherapy in adults with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Taoyuan City) |
| Status | Recruiting |
| Started | May 23, 2018 |
| Main results expected | December 27, 2025 |
| Study ends | April 30, 2026 |
| Registry record updated | December 3, 2025 |
| Trial ID | NCT07260370 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20 or older who have been diagnosed with cancer and are scheduled to receive immunotherapy and can give informed consent are ideal candidates.
✕Probably not a fit
Patients under age 20, those who decline participation, or those unable to provide the required blood samples are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will enroll 300 adults with physician-diagnosed cancer who are starting immunotherapy. Participants will give small blood samples (two 10 mL tubes, up to three times) before and after treatment and investigators may review existing pathology tissue when needed. The project will compare quantities of free microRNAs, counts of circulating tumor cells, and surface antigen expression on both blood cells and available tumor tissue. Statistical analyses will identify patterns that correlate with treatment status and antigen expression.
Why it matters
Potential benefit: If successful, the results could help clinicians use blood-based microRNA and circulating tumor cell measurements to monitor or predict response to immunotherapy.
How similar studies have gone: Previous research has shown that circulating tumor cells and microRNA can reflect cancer biology and sometimes predict therapy response, but findings have been mixed and these biomarkers are not yet standard clinical tools.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged above 20 years. 2. A patient diagnosed with cancer with immunotherapy 3. Competent to give informed consent and agree to join the study. Exclusion Criteria: 1. Aged \< 20 years. 2. Refuse to join the study
Where it's running
-
Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan Recruiting
Study contacts
- Principal investigator: Chia-Hsun Hsieh, PhD — Division of Oncology, Chang Gung Memorial Hospital
- Study coordinator: Chia-Hsun Hsieh, PhD
- Email: wisdom5000@gmail.com
- Phone: 0975366137
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum
Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.
-
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer
In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.
-
Short-course radiotherapy followed by PD-1 inhibitor and FOLFOX vs standard chemoradiotherapy for high‑risk locally advanced lower rectal cancer
This trial tests whether giving a short course of radiotherapy followed by a PD-1 inhibitor and FOLFOX can be better than the usual long-course chemoradiotherapy for adults with high‑risk, locally advanced, pMMR/MSS lower rectal cancer.
-
Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy
This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.